In line with our observations, studies conducted by Morohashi et al. and Szasz et al. with a smaller sample of BCs reported that CLDN1-negative or -low expression was associated with tumor recurrence in different subtypes of BC (P<0.001 and P = 0.038) [16], [29]. Here, CLDN1 is linked to neoplasm.